Announcements Trials
Browse Landscape

Phase

Phase 1 16Phase 2 6Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 31Gastrointestinal 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 699Lung Neoplasms 297Small Cell Lung Carcinoma 149Colorectal Neoplasms 113Melanoma 106Neoplasms 93Breast Neoplasms 93Ovarian Neoplasms 92Neoplasm Metastasis 85Squamous Cell Carcinoma of Head and Neck 83Stomach Neoplasms 81Pancreatic Neoplasms 78Carcinoma, Renal Cell 66Triple Negative Breast Neoplasms 63Esophageal Neoplasms 51Endometrial Neoplasms 48Uterine Cervical Neoplasms 47Head and Neck Neoplasms 47Mesothelioma 42Mesothelioma, Malignant 41Sarcoma 40Prostatic Neoplasms 36Urinary Bladder Neoplasms 34Carcinoma, Transitional Cell 32Colonic Neoplasms 31Carcinoma, Hepatocellular 31Adenocarcinoma of Lung 31Carcinoma 26Recurrence 21Thyroid Neoplasms 20

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Uveal Melanoma × Thoracic × Clear all
NCT04130516 2025-12-18

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

Linnaeus Therapeutics, Inc.

Phase 1/2 Recruiting
200 enrolled
DermatologicGastrointestinalThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡